Simon Mallal Selected Research

abacavir (Ziagen)

1/2015	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.
1/2015	T cell-mediated hypersensitivity reactions to drugs.
1/2015	Abacavir-reactive memory T cells are present in drug naïve individuals.
1/2014	Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
8/2012	HLA and pharmacogenetics of drug hypersensitivity.
1/2009	Successful translation of pharmacogenetics into the clinic: the abacavir example.
11/2008	Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.
6/2008	Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
4/2008	High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
2/2008	HLA-B*5701 screening for hypersensitivity to abacavir.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon Mallal Research Topics

Disease

24	Hypersensitivity (Allergy) 01/2018 - 05/2003
23	Infections 01/2022 - 06/2005
10	HIV Infections (HIV Infection) 01/2018 - 03/2003
8	Drug Hypersensitivity (Drug Allergy) 01/2021 - 01/2006
8	Drug-Related Side Effects and Adverse Reactions 09/2017 - 12/2004
5	Disease Progression 11/2021 - 12/2004
4	Parkinson Disease (Parkinson's Disease) 11/2021 - 01/2017
4	Dengue (Dengue Fever) 12/2017 - 10/2016
4	Drug Hypersensitivity Syndrome 01/2017 - 03/2004
4	Lipodystrophy 01/2005 - 05/2003
2	COVID-19 01/2021 - 12/2020
2	Tetanus 01/2018 - 01/2017
2	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2018 - 08/2012
2	Hepatitis 08/2014 - 01/2005
2	Chronic Hepatitis C 09/2011 - 04/2009
2	Human Influenza (Influenza) 05/2009 - 10/2007
2	Lactic Acidosis 12/2004 - 02/2002
1	Atherosclerosis 07/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2022
1	Stomach Diseases 01/2022
1	Vasculitis (Vasculitides) 01/2022
1	Whooping Cough (Pertussis) 11/2021
1	Pathologic Constriction (Stenosis) 01/2021
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2021
1	Yellow Fever 11/2020
1	Breast Neoplasms (Breast Cancer) 11/2020
1	Triple Negative Breast Neoplasms 11/2020
1	Neoplasms (Cancer) 11/2020
1	Immunoglobulin G4-Related Disease 01/2019
1	Genomic Instability 10/2018
1	Polyploidy 10/2018
1	Stomach Neoplasms (Stomach Cancer) 10/2018
1	Iron Deficiencies 10/2018
1	Overweight 01/2018
1	Zika Virus Infection 12/2017
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2017
1	Thrombocytopenia (Thrombopenia) 09/2017
1	Autoimmune Diseases (Autoimmune Disease) 09/2017
1	Inflammation (Inflammations) 12/2015
1	Adenocarcinoma 12/2015
1	Histoplasmosis 05/2015
1	Mediastinal Fibrosis 05/2015
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2015

Drug/Important Bio-Agent (IBA)

21	abacavir (Ziagen)FDA Link 01/2015 - 05/2003
20	HLA-B Antigens (HLA-B)IBA 01/2018 - 03/2004
16	EpitopesIBA 07/2022 - 06/2005
14	Pharmaceutical PreparationsIBA 01/2018 - 09/2004
9	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2008
9	Peptides (Polypeptides)IBA 12/2017 - 05/2009
8	AntigensIBA 11/2021 - 09/2004
7	HLA-B57 antigenIBA 01/2018 - 06/2005
7	Nevirapine (Viramune)FDA Link 01/2017 - 01/2005
5	Proteins (Proteins, Gene)FDA Link 11/2020 - 12/2012
5	Reverse Transcriptase InhibitorsIBA 06/2008 - 02/2002
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2022 - 01/2015
4	SynucleinsIBA 11/2021 - 01/2017
4	VaccinesIBA 04/2017 - 04/2009
4	NucleosidesIBA 12/2004 - 02/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 04/2016
3	HLA-DRB1 Chains (HLA DRB1)IBA 10/2016 - 01/2005
2	CytokinesIBA 07/2022 - 01/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 03/2004
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 11/2012
2	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2012
2	SaltsIBA 10/2018 - 12/2015
2	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2018 - 01/2017
2	efavirenz (Sustiva)FDA Link 01/2018 - 02/2006
2	Amino Acids FDA Link 01/2018 - 02/2011
2	Attenuated VaccinesIBA 12/2017 - 01/2017
2	Carbamazepine (Tegretol)FDA LinkGeneric 01/2015 - 06/2008
2	Allopurinol (Remid)FDA LinkGeneric 01/2015 - 06/2008
2	Viral ProteinsIBA 08/2013 - 06/2012
2	HLA-C Antigens (HLA-C)IBA 04/2013 - 09/2011
2	Biomarkers (Surrogate Marker)IBA 11/2008 - 01/2008
2	LigandsIBA 06/2008 - 02/2005
1	Apolipoproteins B (ApoB)IBA 07/2022
1	HLA-DPB1 antigen (HLA DPB1)IBA 01/2022
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2022
1	5' Untranslated Regions (5' UTR)IBA 01/2022
1	Subgenomic RNAIBA 01/2022
1	Myeloblastin (Proteinase 3)IBA 01/2022
1	AutoantigensIBA 11/2021
1	Herpes Zoster VaccineIBA 11/2020
1	B7-H1 AntigenIBA 11/2020
1	130-nm albumin-bound paclitaxelIBA 11/2020
1	Immunoglobulin G (IgG)IBA 01/2019
1	OligopeptidesIBA 01/2018
1	Tenofovir (Viread)FDA Link 01/2018
1	Emtricitabine (Emtriva)FDA Link 01/2018
1	Rilpivirine (TMC-278)IBA 10/2017
1	HLA-DQB1 antigen (HLA DQB1)IBA 10/2017
1	Heparin (Liquaemin)FDA LinkGeneric 09/2017
1	KIR ReceptorsIBA 09/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017
1	Dengue VaccinesIBA 01/2017
1	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 01/2015

Therapy/Procedure

14	Therapeutics 03/2014 - 03/2003
1	Drug Therapy (Chemotherapy) 11/2020
1	Neoadjuvant Therapy 11/2020
1	Immunotherapy 11/2020